Scarica l'app Stockscreener
5.37
6.76%
0.34
Dopo l'orario di chiusura:
5.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.03
Aprire:
$5.1
Volume 24 ore:
6.08M
Relative Volume:
0.70
Capitalizzazione di mercato:
$914.41M
Reddito:
-
Utile/perdita netta:
$-25.94M
Rapporto P/E:
-18.72
EPS:
-0.2869
Flusso di cassa netto:
$-30.62M
1 W Prestazione:
-2.89%
1M Prestazione:
+49.58%
6M Prestazione:
+190.27%
1 anno Prestazione:
+362.93%
Intervallo 1D:
$5.10
$5.60
Intervallo di 1 settimana:
$4.93
$6.14
Portata 52W:
$0.9516
$6.14
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Nome
Sellas Life Sciences Group Inc
Settore
Industria
Telefono
(646) 200-5278
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
5.37 | 914.41M | 0 | -25.94M | -30.62M | -0.2869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Iniziato | Oppenheimer | Outperform |
| 2018-04-02 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-19 | Aggiornamento | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
A Look At SELLAS Life Sciences Group (SLS) Valuation After Its Sharp Recent Share Price Gains - simplywall.st
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.3% HigherWhat's Next? - MarketBeat
SELLAS enrolls first patient in Phase 2 AML trial of SLS009 - Investing.com India
SLS stock in spotlight: First AML patient enrolled in phase 2 leukemia trial - MSN
SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial - Asianet Newsable
According to the latest merger agreement terms, Signature Bank shareholders will receive an equity allocation at a ratio of 2.63 shares of Esquire Financial Holdings Inc. for each share of Signature stock. - Bitget
Major Bank Ratings | Evercore ISI: Raises Ryanair target price to $80, rating upgraded to "Outperform" - Bitget
Sellas announces enrollment of first patient in Phase 2 SLS009 trial - TipRanks
SELLAS Life Sciences Group Inc. announced that the first patient has been enrolled in the clinical trial of its innovative drug SLS009 for first-line treatment of newly diagnosed acute myeloid leukemia (AML). - Bitget
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - The Manila Times
Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - marketscreener.com
SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
SELLAS Strengthens Capital Base Through Warrant Exercises - TipRanks
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds - Investing.com UK
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds By Investing.com - Investing.com Australia
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail - Stocktwits
SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 6.2%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Aug Catalysts: Will SELLAS Life Sciences Group Inc benefit from seasonality2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS Life Sciences (SLS) Is Up 18.0% After Positive AML Trial Updates – What’s Changed - Yahoo Finance
SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month HighStill a Buy? - MarketBeat
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout - Asianet Newsable
Trade Recap: Can SELLAS Life Sciences Group Inc beat the S P 5002026 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout - Stocktwits
Assessing SELLAS Life Sciences Group (SLS) Valuation After Recent Leukemia Trial Updates - Yahoo Finance
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout - Stocktwits
Sellas Life Sciences draws retail buzz on SLS009 trial momentum – stock soars in pre-market - MSN
Assessing SELLAS Life Sciences Group (SLS) Valuation After New Phase 3 REGAL Trial Progress News - simplywall.st
Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst - Seeking Alpha
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SELLAS Life Sciences (SLS) Is Up 21.8% After REGAL Trial Clears Key Continuation ReviewWhat's Changed - simplywall.st
Wall Street Recap: Can SELLAS Life Sciences Group Inc beat the S P 500July 2025 Sentiment & Safe Entry Trade Signal Reports - baoquankhu1.vn
What's Going With SELLAS Life Sciences Stock On Wednesday? - Bitget
Bull Run: Will SELLAS Life Sciences Group Inc benefit from green energy policiesWeekly Market Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
SLS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SLS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SLS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
SLS Technical Analysis & Stock Price Forecast - Intellectia AI
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Asianet Newsable
Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):